By targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1), immune checkpoint drugs have shown efficacy against various tumor types. This evidence concerns the gene PDCD1 and neoplasm.